IVERIC bio Inc

IVERIC bio — Investor Presentation (August 2019)

57 slides from IVERIC bio's investor presentation, Aug 14, 2019

  1. Slide 1: IVERIC bio August 2019

    - IVERIC NASDAQ: ISEE August 2019

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements Any statements in this presentation about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include a

  3. Slide 3: A leader in developing gene therapy treatments for orphan inherited retinal diseases

    A leader in developing transformative gene therapy treatments for patients with orphan inherited retinal diseases

  4. Slide 4: Well-positioned as a Leader in Orphan Inherited Retinal Disease Gene Therapy

    Well-positioned as a Leader in Orphan Inherited Retinal Disease Gene Therapy Compelling Science – Clear rationale for product constructs & strong pre-clinical animal data High Unmet Medical Need & Potential Best-in-Class Significant Commercial Opportunity – Program criteria: large epidemiology, unme

  5. Slide 5: Strong Senior Management with Significant Execution Experience

    Strong Senior Management with Significant Execution Experience and Domain Expertise in Retina Key Management Experience Glenn Sblendorio Chief Executive Officer Kourous A. Rezaei, MD Chief Medical Officer David F. Carroll Chief Financial Officer Keith Westby Chief Operating Officer Evelyn Harrison C

  6. Slide 6: IVERIC bio Gene Therapy Pipeline

    IVERIC bio Gene Therapy Pipeline Goal: Broadest and deepest inherited retinal disease portfolio Indication Research Pre-clin. Phase 1/2 Phase 3 Planned Milestones IC-100: RHO-adRP • Phase 1/2: plan to initiate 2H 2020 (AAV5) IC-200: BEST1-Related • Phase 1/2: plan to initiate 1H 2021 IRDs (AAV2) min

  7. Slide 7: Patient Populations for Orphan IRDs

    Patient Populations for Orphan IRDs1 2 Portfolio of Programs has multi-billion $ cumulative net sales potential ~62K - 77K Stargardt ~20K - 62K USH2A ~10K - 40K BEST1 ~11K ~2.7K - 4.1K RHO-adRP LCA10 1 Estimated combined patient populations in US and EU5 for each indication based on published litera

  8. Slide 8: Scientific Collaborations: Leading Academic Gene Therapy Centers

    Scientific Collaborations: Leading Academic Gene Therapy Centers 8

  9. Slide 9: Manufacturing Strategy

    Manufacturing Strategy Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy – Proven expertise in gene therapy manufacturing – World-class and state-of-the-art GMP gene therapy biomanufacturing capabilities Paragon collaboration includes process development and manufacturing of

  10. Slide 10: Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa IC-100

    Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa IC-100: scAAV2/5-H1p-shRNA820 -hOP-RHO820 10

  11. Slide 11: IC-100: RHO-adRP Phase 1/2 Planned to Initiate in 2H 2020

    IC-100: RHO-adRP Phase 1/2 Planned to Initiate in 2H 2020 Significant Commercial Opportunity – Estimated prevalence: ~11K in the US & EU5 combined1 – High unmet need: Bilateral degeneration of rod and cone photoreceptors, leading to night blindness and progressive visual impairment – Potentially fir

  12. Slide 12: Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa

    Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Retinitis pigmentosa (RP): most prevalent inherited retinal dystrophy Rhodopsin Molecule Bilateral degeneration of rod and cone photoreceptors that ultimately leads to night blindness and progressive visual impairment adRP: The most common a

  13. Slide 13: ADRP Caused by RHO Mutation

    ADRP Caused by RHO Mutation Phenotypic feature in a patient with RHO mutation showing inferior photoreceptor degeneration corresponding to superior visual field loss Normal RHO-adRP Superior visual field loss Loss of photoreceptors 13 Source: Invest Ophthalmol Vis Sci. 2016;57:4847–4858.

  14. Slide 14: Proof of Concept in Mouse and Naturally Occurring Canine Models

    Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa: Proof of Concept in Mouse and Naturally Occurring Canine Models http://www.pnas.org/content/early/2018/08/14/1805055115 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327607/ 14

  15. Slide 15: Vector Construct for IC-100

    Vector Construct for IC-100 that is Used for: POC Canine and Planned GLP Tox and Clinical Studies Vector: AAV2/5 (serotype 5 capsid and type 2 terminal repeats (TRs)) Construct: scAAV2/5-H1p-shRNA820-hOP-RHO820, human opsin promoter Delivery: Single subretinal injection AAV2/5 Capsid hOP pro. WtTR S

  16. Slide 16: Canine Model Proof-of-Concept: Rescue in Naturally Occurring RHO Mutant Dogs

    Canine Model Proof-of-Concept: Rescue in Naturally Occurring RHO Mutant Dogs heterozygous for T4R Mutant Allele (RHOT4R/+) scAAV2/5-H1p-shRNA820 -hOP-RHO820 EM424-OS (displayedOCT as OD) EM425-OS (displayed as OD) Untreated Area: Untreated Area: Photoreceptor Photoreceptor degeneration GFP degenerat

  17. Slide 17: Canine Model Proof-of-Concept: Histology and ERG

    Canine Model Proof-of-Concept: Histology - Preservation of Retinal Anatomy | ERG - Preservation of Retinal Function scAAV2/5-H1p-shRNA820 -hOP-RHO820: Rescued Outer Retina TREATED UNTREATED OCT Transition Zone Anatomy EM424OS Function (ERG) Green: scAAV2/5-RHO820 -shRNA820 RED: Balanced Salt Solutio

  18. Slide 18: IC-100: RHO-adRP Program Summary

    IC-100: RHO-adRP Program Summary Potentially first in class and best-in-class No clinical stage gene therapy competition Mutation independent strategy – >150 identified rhodopsin gene (RHO) mutations Knockdown and replacement with a single AAV vector – Suppression of endogenous mutant toxic rhodopsi

  19. Slide 19: BEST1 Related Retinal Diseases IC-200: AAV2-BEST1

    BEST1 Related Retinal Diseases IC-200: AAV2-BEST1 19

  20. Slide 20: IC-200: BEST1 Phase 1/2 Planned to Initiate in 1H 2021

    IC-200: BEST1 Phase 1/2 Planned to Initiate in 1H 2021 Significant Commercial Opportunity – Estimated prevalence: ~10K - 40K in the US & EU5 combined1 – High unmet need: Bilateral disease caused by mutations in the BEST1 gene, which leads to vitelliform lesion in macular region, macular atrophy and

  21. Slide 21: BEST1 - Related Inherited Retinal Diseases

    BEST1 - Related Inherited Retinal Diseases BEST 1 is predominantly expressed in Model of Human Best1 the retinal pigment epithelium (RPE) An integral membrane protein localized to the basolateral plasma membrane Over 200 mutations throughout the entire BEST1 gene have been reported Prevalence estima

  22. Slide 22: Best Disease (Best Vitelliform Macular Dystrophy)

    Best Disease (Best Vitelliform Macular Dystrophy) An orphan inherited retinal disease caused by mutations in the BEST1 gene, autosomal dominant, generally affecting both eyes Best1 protein helps regulate chloride ion traffic in retinal cells Dysregulation of intracellular Ca2+ and Cl- leads to micro

  23. Slide 23: Best Disease Stages

    Best Disease (Best Vitelliform Macular Dystrophy) Fundus OCT Disease Stages 1. Subclinical Stage 2. Vitelliform Stage Development of microdetatchment 3. Hypopyon stage Progression of microdetatchment 4. Vitelliruptive Stage Thinning and atrophy 5. Macular Atrophy Stage 23 Source: Retina 2018; 38:104

  24. Slide 24: IC-200: Vector Construct

    IC-200: Vector Construct Vector: AAV2/2 (serotype 2 capsid and type 2 terminal repeats (TRs)) Construct: AAV2/2- BEST1, human VMD2 promoter Delivery: Single subretinal injection AAV2/2 Capsid ITR VMD2/BEST1 promoter BEST1 SV40 Poly A ITR Produces healthy wildtype BEST1 protein 24 Sources: PNAS 2018,

  25. Slide 25: AAV2 Vectors

    AAV2 Vectors The most widely used AAV vector in pre-clinical and clinical trials targeting the RPE cells AAV2/2 vector serotype has been reported: Safe RPE - Specific Stable AAV2 + hVMD2 (BEST1) promoter: specific + exclusive tropism for RPE cells Native GFP Fluorescence RPE Anti-GFP Antibody RPE 25

  26. Slide 26: Best1 Overexpression in Wild Type Canine RPE

    Best1 Overexpression in Wild Type Canine RPE Endogenous Best1 Expression Transgene Best1 Over-Expression Non-transfected Retina Transfected Retina 26 Source: PLoS One 2013;8:e75666.

  27. Slide 27: Best1 Overexpression Reported Safe in Wild Type Canine RPE

    Best1 Overexpression Reported Safe in Wild Type Canine RPE Control AAV2-hBEST1 Bleb Intact Photoreceptor Layer 27 Sources: PLoS One 2013;8:e75666; Karina E. Guziewicz et al. University of Pennsylvania

  28. Slide 28: Best1 Related Animal Model: Canine Multifocal Retinopathy

    Best1 Related Animal Model: Canine Multifocal Retinopathy (cmr) Spontaneous early-onset of disease Featuring the full spectrum of clinical and histologic features observed in BEST1-affected patients Caused by autosomal recessive mutations in BEST1 dog ortholog The 3 identified mutations model all ma

  29. Slide 29: Human Disease ~ Naturally Occurring Canine Model

    Human Disease ~ Naturally Occurring Canine Model 29 Courtesy: Karina E. Guziewicz et al. University of Pennsylvania

  30. Slide 30: BEST1 Mutation: Leads to Abnormal RPE Apical Microvilli

    BEST1 Mutation: Leads to Abnormal RPE Apical Microvilli Microvilli 30 Source: Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):E2839-E2848.

  31. Slide 31: Proof of Concept in Naturally Occurring BEST1 Canine Model

    BEST1 Related Inherited Retinal Diseases Proof of Concept in Naturally Occurring BEST1 Canine Model, 3 Different Mutations http://www.pnas.org/content/early/2018/02/28/1720662115 31

  32. Slide 32: Canine Model: Resolution of Retinal Microdetachment

    Canine Model Proof-of-Concept: Resolution of Retinal Microdetachment after AAV2-hBEST1 Gene Therapy Control Injection with BSS AAV Therapy with Human Transgene Before injection BSS: 87 wks post inj Before injection AAV: 103 wks post inj Microdetachment Microdetachment Enlargement Microdetachment Mic

  33. Slide 33: IC-200: BEST1 Program Summary

    IC-200: BEST1 Program Summary Potentially first in class and best-in-class No clinical stage competition currently Proof of concept established in the naturally occurring autosomal recessive BEST1 canine model – 3 different mutations – Long-term preservation of retinal structure Clear path to IND su

  34. Slide 34: Minigene Programs

    Minigene Programs iVERIC bio

  35. Slide 35: AAV Vectors Preferred for Ocular Gene Therapy

    AAV Vectors Preferred for Ocular Gene Therapy FDA Approved (Luxturna®) Extensive experience with intraocular application in both humans and animal models Well documented safety profile Tropism for retinal tissue Alternative technologies have inherent challenges (e.g. Lentivirus) Limited packaging ca

  36. Slide 36: Current minigene Programs

    Current minigene Programs Leber Congenital Amaurosis (LCA10): miniCEP290 – Estimated Prevalence: ~2.7K - 4.1K in US & EU5 combined Autosomal Recessive Stargardt Disease: miniABCA4 – Estimated Prevalence: ~62K - 77K US & EU5 combined Usher Syndrome Type 2A & USH2A related nonsyndromatic Autosomal Rec

  37. Slide 37: miniCEP290: LCA10 Potential Product Candidate

    miniCEP290: LCA10 Potential Product Candidate Significant Commercial Opportunity – Estimated Prevalence: ~2.7K - 4.1K in US & EU5 combined1 – High Unmet Need: most common cause of LCA with early onset vision loss – Potential for best-in-class: Mutation independent strategy compared to gene editing o

  38. Slide 38: CEP290 in Leber Congenital Amaurosis Type

    CEP290 in Leber Congenital Amaurosis Type 10 Light Photoreceptor: The outer segments are filled with membranous discs with rhodopsin, the receptor molecule that initiates a X transduction cascade turning photons into electrical signals X Signal output to cells in theX retina/visual cortex in brain 3

  39. Slide 39: Leber Congenital Amaurosis Type (CEP290)

    Leber Congenital Amaurosis Type 10 (CEP290) • CEP290 mutations: one of the most common causes of LCA • Estimated prevalence: ~2.7K - 4.1K in the US & EU5 combined based on published literature • Early onset vision loss • Preserved outer retinal structure in the foveal area • Extinguished Electroreti

  40. Slide 40: miniCEP290: Preliminary Proof-of-Concept in a Mouse Model of LCA

    miniCEP290: Leber Congenital Amaurosis (CEP290): Preliminary Proof-of-Concept in a Mouse Model of LCA (CEP290) http://doi.org/10.1089/hum.2017.049 40

  41. Slide 41: miniCEP290: LCA10 Preliminary Proof-of-Concept

    miniCEP290: LCA10 Preliminary Proof-of-Concept Preliminary proof-of-concept shown in mouse model  ongoing sponsored research to optimize and select lead product candidate MiniCEP290580-1180 GFP (Control) miniCEP290 Preserved photoreceptors (Control) 8 x 109 vg/µl into the subretinal space of Cep290

  42. Slide 42: miniCEP290: LCA10 Potential Product Candidate

    miniCEP290: LCA10 Potential Product Candidate Potentially best-in-class Mutation independent strategy Replacement of the mutated gene with a novel miniCEP290 in AAV Preliminary proof-of-concept in mouse model – Preservation of retinal structure and function 42

  43. Slide 43: Autosomal Recessive Stargardt Disease (ABCA4)

    Autosomal Recessive Stargardt Disease (ABCA4) The most common inherited macular dystrophy in both children and adults Prevalence estimates range between ~62K - 77K in US & EU5 combined ABCA4 gene makes a protein that helps clearing away visual cycle byproducts inside retinal cells Macular Atrophy AB

  44. Slide 44: miniABCA4: Autosomal Recessive Stargardt Disease

    miniABCA4: Autosomal Recessive Stargardt Disease (ABCA4) ABCA4 cDNA size: ~7kb and contains multiple functional elements Generate MiniABCA4 Fragments Clone into AAV Vectors Demonstrate In Vitro Protein Expression Proof of Concept (in vivo) Illustration purposes only 44

  45. Slide 45: miniUSH2A: Overview

    miniUSH2A: Overview Disease: Mutations in the USH2A gene lead to visual loss in – Usher syndrome type 2A: Prevalence estimates range between ~13K – 55K in US & EU5 combined based on published literature – USH2A related nonsyndromatic autosomal recessive retinitis pigmentosa: Prevalence estimate of ~

  46. Slide 46: AAV Gene Delivery Technology

    AAV Gene Delivery Technology • Strategic collaboration with Dr. Guangping Gao – Renowned AAV Pioneer at UMass Medical School • Pilot study to identify and evaluate various AAV capsids and routes of administration • Histology data expected to be received 2H’19 46

  47. Slide 47: IVERIC bio Gene Therapy Pipeline

    IVERIC bio Gene Therapy Pipeline Goal: Broadest and deepest inherited retinal disease portfolio Indication Research Pre-clin. Phase 1/2 Phase 3 Planned Milestones IC-100: RHO-adRP • Phase 1/2: plan to initiate 2H 2020 (AAV5) IC-200: BEST1-Related • Phase 1/2: plan to initiate 1H 2021 IRDs (AAV2) min

  48. Slide 48: Appendix (Therapeutic Assets Available for Partnering)

    Appendix (Therapeutic Assets Available for Partnering) 48

  49. Slide 49: Zimura Clinical Programs: Update

    Zimura Clinical Programs: Update Research/ Indication Pre-clinical Phase 1 Phase 2 Phase 3 Status OPH2003: GA secondary to • Phase 2b ongoing Dry AMD (monotherapy) • Initial top-line data expected Q4 2019 OPH2005: STGD1 • Phase 2b ongoing (monotherapy) • Initial top-line data expected 2H 2020 # of P

  50. Slide 50: OPH2003 Geographic Atrophy (GA) Secondary to Dry AMD

    OPH2003 Geographic Atrophy (GA) Secondary to Dry AMD 50

  51. Slide 51: OPH2003: Zimura in GA Secondary to Dry AMD

    OPH2003: Zimura in GA Secondary to Dry AMD – Ongoing Phase 2b, randomized, double masked, sham controlled clinical trial 3 Cohorts will be included for statistical analysis: – Zimura 4mg dose – Zimura 2mg dose – Sham ~ 286 subjects were enrolled for monthly treatment with Zimura or Sham for 18 month

  52. Slide 52: OPH2005 Autosomal Recessive Stargardt Disease

    OPH2005 Autosomal Recessive Stargardt Disease Orphan Indication 52

  53. Slide 53: OPH2005: Zimura in AR Stargardt Disease

    OPH2005: Zimura in AR Stargardt Disease – Ongoing Phase 2b, randomized, double masked, sham controlled clinical trial Two arms: – Zimura 4mg – Sham ~ 95 subjects were enrolled for treatment with Zimura or Sham for 18 months Primary Efficacy Endpoint – Mean rate of change over 18 months in the area o

  54. Slide 54: HtrA1 Inhibitor Program

    HtrA1 Inhibitor Program iVERIC bio

  55. Slide 55: HtrA1 Inhibitor Program Acquired Inception 4

    HtrA1 Inhibitor Program Acquired Inception 4, a privately held company backed by Versant Ventures – Gained worldwide development and commercial rights to HtrA1 inhibitor program to treat age-related retinal diseases – ISEE obtained ~$6.1 million in cash – Versant a major new investor in ISEE (~5.2 m

  56. Slide 56: HtrA1 Inhibitor Program: Small Molecules with High Affinity and Specificity

    HtrA1 Inhibitor Program: Small Molecules with High Affinity and Specificity for HtrA1 Strong genetic link between HtrA1 & AMD: – Homozygotes have ~8.2 fold increased risk AMD patients overexpress HtrA1: – Increased intracellular expression of HtrA1 inside the RPE cells of AMD patients – Increased Ht

  57. Slide 57: HtrA1 Inhibitor Program

    HtrA1 Inhibitor Program Formulation development activities ongoing Small scale API manufacturing ongoing CMO selection process underway for API scale-up and GMP manufacturing Animal PK/ formulation tolerability studies planned 57

IVERIC bio — Investor Presentation (August 2019) on 6ix